is the new congress ready webinar to lower drug …...2019/02/02  · chip roy mark green elijah...

Is the new Congress readyWEBINAR

to lower drug costs?With STAT’s Washington Correspondents,

Lev Facher and Nicholas Florko

Agenda

1. The Midterms

2. The Trump Administration

3. Legislation to Watch

4. Investigations

5. Lobbying

The Midterms

Slide 4

GOP holds Senate, Dems gain 40 House seats

Senate Majority Leader Mitch McConnell (R-Ky.) Speaker of the House Nancy Pelosi (D-Calif.)

Slide 5

The House Ways & Means Committee

Rep. Richard Neal (D-Mass.) Rep. Lloyd Doggett (D-Texas)

Slide 6

The House Energy & Commerce Committee

Rep. Anna Eshoo (D-Calif.) Rep. Frank Pallone (D-N.J.)

Slide 7

The House Energy & Commerce Committee

“We are going to do at least one diabetes hearing.”

Rep. Diana DeGette (D-Colo.)

Slide 8

House Freedom Caucus

The House Oversight Committee

Jim Jordan Mark Meadows Justin Amash

Paul Gosar Jody Hice

Michael Cloud Ralph Norman

Chip Roy Mark Green

Elijah Cummings Carolyn Maloney

Lacy Clay Jamie Raskin

Katie Hill Peter Welch

Mark DeSaulnierBrenda Lawrence

Ro KhannaJimmy Gomez

Alexandria Ocasio-CortezAyanna Pressley

Rashida Tlaib

House Progressive Caucus

Slide 9

Senate Finance Committee

Sen. Chuck Grassley (R-Iowa) Sen. Ron Wyden (D-Ore.)

Slide 10

Bipartisan Collaboration on SFC

“This legislation is a significant step forward to fixing the problems in our health care system that have allowed pharmaceutical manufacturers to price gouge taxpayers and consumers for too long.” —Sen. Grassley on the Right Rebate Act of 2018, co-sponsored with Wyden

Slide 11

The Senate HELP Committee

Sen. Lamar Alexander (R-Tenn.) Sen. Mitt Romney (R-Utah)

Slide 12

Sen. Lindsey Graham (R-S.C.)

The Senate Judiciary Committee

The Trump Administration

Slide 14

Joe Grogan, Chair, Domestic Policy Council Former Head of Federal Affairs, Gilead

Shahira Knight, White House Director of Legislative Affairs

The White House

Slide 15

Alex Azar, HHS SecretaryFormer President, Lilly USA

John O’Brien, Senior Advisor to the Secretary for Drug Pricing Reform

Dept. of Health and Human Services

Legislation to Watch

Slide 17

Legislation that will be taken seriously

→ Reforms for Medicare Part D

→ CREATES Act

→ Preserve Access to Affordable Generics Act

(Pay for Delay)

Slide 18

Messaging from 2020 candidates

→ Bernie Sanders’ international price index

→ Elizabeth Warren’s generic drug manufacturing bill

→ Klobuchar & Harris’ bill to block price increases

→ Various iterations of Medicare negotiation

→ Klobuchar, Brown & Harris’ drug exclusivity bill

Slide 19

Wild cards

→ Grassley-Klobuchar personal drug importation

→ PBM transparency bills

→ Cassidy-Warner value-based pricing bill

→ Wyden’s bill requiring justification for price spikes

→ Wyden-Grassley bill on Medicaid rebates

Investigations

Slide 21

Members & Companies Impacted

Senate FinanceAbbVie, AstraZeneca, Bristol-Myers Squibb,

Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Eli Lilly,

Novo Nordisk

House OversightAstraZeneca, Teva,

Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt,

Amgen, Pfizer, Novo Nordisk, Sanofi, AbbVie

House Energy & Commerce

Sanofi, Eli Lilly, Novo Nordisk

Source: Giphy

Lobbying

Slide 24

Annual Lobbying by PhRMA

‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16 ‘17 ‘18

$6M

$12M

$18M

$24M

$30M

$0M

YEAR

TOTA

L

Slide 25

Other groups to watch

Q&A

Thanks!@levfacher @NicholasFlorko